Lyell Immunopharma

Lyell Immunopharma is using the latest insights in immunology to reprogram T cells to cure cancer. CAR T cells have had most success so far in treating patients with B cell lymphomas. However, around 90% of all cancers are solid tumors where only limited success with cell therapies has been seen. Lyell is using their proprietary epigenetic and genetic reprogramming technologies to develop cell therapies to address these tumors for reliable and curative responses. Lyell’s approach involves identifying the “active ingredient” of adoptive cell therapies to either overcome loss of T cell function or to create T cell populations with durable stemness to infiltrate tumors. Lyell’s lead product, LYL797 is in Phase 1 clinical trials for non-small cell lung cancer, with other products in the pipeline.

Jobs:

Quality Assurance, Sr Associate

Bothell, WA|1 day ago

Apply

Senior Clinical Trial Assistant

Seattle, WA|2 days ago

Apply

Associate Director, Manufacturing Science and Technology

Bothell, WA|4 days ago

Apply

Clinical Trial Assistant

Seattle, WA|8 days ago

Apply

Executive Assistant II

South San Francisco, CA|18 days ago

Apply

Scientist I

South San Francisco, CA|28 days ago

Apply

Vice President, Legal

South San Francisco, CA|35 days ago

Apply

Vice President,Intellectual Property

South San Francisco, CA|44 days ago

Apply

Clinical Trials Manager

Seattle, WA|81 days ago

Apply

Associate Director, Statistical Programming

WA|81 days ago

Apply

Quality Assurance Specialist

Bothell, WA|86 days ago

Apply

Vice President, Business Development and Corporate Strategy

South San Francisco, CA|100+ days ago

Apply

Medical Director

Seattle, WA|100+ days ago

Apply